Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Cullinan Therapeutics To Pursue Development Of CLN-978 In Autoimmune Diseases, With Systemic Lupus Erythematosus As First Indication; Discontinued Enrollment In Its B-NHL Study To Focus Ongoing Development On Autoimmune Indications

Author: Benzinga Newsdesk | April 16, 2024 07:44am

CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication

Clinical observations from CLN-978 B-NHL study show rapid, deep, and sustained B cell depletion and clinical activity

Corporate name change to Cullinan Therapeutics reflects strategic expansion into autoimmune diseases

Cullinan Therapeutics to host a virtual investor event taking place on April 16 at 8:00 am ET

Posted In: CGEM